Literature DB >> 6326659

Levels of adenylate deaminase, adenylate kinase, and creatine kinase in frozen human muscle biopsy specimens relative to type 1/type 2 fiber distribution: evidence for a carrier state of myoadenylate deaminase deficiency.

W N Fishbein, V W Armbrustmacher, J L Griffin, J I Davis, W D Foster.   

Abstract

Myoadenylate deaminase deficiency is believed to reflect a genetic deficiency of skeletal muscle, but its pattern of inheritance has not been established. We examined, histochemically and by quantitative biochemical assay, muscle biopsy specimens from 3 putative carriers of this disorder. Adenylate kinase and creatine kinase were assayed in parallel with adenylate deaminase in order to establish enzyme activity ratios and the variation of each enzyme with fiber-type distribution. Control tissue consisted of 34 biopsy specimens without notable abnormalities from 30 patients, and included 4 specimen pairs with disparate fiber-type contributions. By linear regression analysis, adenylate deaminase level averaged 2.8-fold higher, and adenylate kinase 4.5-fold higher, in type 2 than in type 1 fibers, whereas creatine kinase level did not differ. The slopes of the regression lines resulting from analysis of the four specimen pairs from individual patients agreed well with the overall regression line in each plot. The 3 putative carriers had adenylate deaminase levels 2.5 to 5.7 times lower than the mean control value for their fiber-type distribution, but at least 20 times higher than their enzyme-deficient kinfolk. This finding indicates that a carrier state does exist, and that the deficiency state reflects an autosomal recessive inheritance pattern. Three additional biopsy specimens were excluded from evaluation when preliminary analysis showed elevated adenylate kinase/adenylate deaminase ratios that were outliers at the 1% level. This result suggests a carrier incidence of 10% in the muscle biopsy specimen population, which would markedly bias population estimates if undetected.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326659     DOI: 10.1002/ana.410150312

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  8 in total

Review 1.  Myoadenylate deaminase deficiency.

Authors:  H H Goebel; A Bardosi
Journal:  Klin Wochenschr       Date:  1987-11-02

Review 2.  Molecular biology of AMP deaminase deficiency.

Authors:  M Gross
Journal:  Pharm World Sci       Date:  1994-04-15

3.  Myoadenylate deaminase deficiency: absence of correlation with exercise intolerance in 452 muscle biopsies.

Authors:  R Mercelis; J J Martin; T de Barsy; G Van den Berghe
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

4.  Comparative enzymology of AMP deaminase, adenylate kinase, and creatine kinase in vertebrate heart and skeletal muscle: the characteristic AMP deaminase levels of skeletal versus cardiac muscle are reversed in the North American toad.

Authors:  W N Fishbein; J I Davis; J W Foellmer
Journal:  J Comp Physiol B       Date:  1993       Impact factor: 2.200

Review 5.  Possible mechanisms of the anaerobic threshold. A review.

Authors:  M L Walsh; E W Banister
Journal:  Sports Med       Date:  1988-05       Impact factor: 11.136

6.  Myoadenylate deaminase deficiency.

Authors:  H H Goebel; A Bardosi; B Conrad; H D Kuhlendahl; S DiMauro; K W Rumpf
Journal:  Klin Wochenschr       Date:  1986-04-01

7.  Diagnostic Algorithm for Glycogenoses and Myoadenylate Deaminase Deficiency Based on Exercise Testing Parameters: A Prospective Study.

Authors:  Fabrice Rannou; Arnaud Uguen; Virginie Scotet; Cédric Le Maréchal; Odile Rigal; Pascale Marcorelles; Eric Gobin; Jean-Luc Carré; Fabien Zagnoli; Marie-Agnès Giroux-Metges
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

8.  Effects of AMPD1 common mutation on the metabolic-chronotropic relationship: Insights from patients with myoadenylate deaminase deficiency.

Authors:  Fabrice Rannou; Virginie Scotet; Pascale Marcorelles; Roxane Monnoyer; Cédric Le Maréchal
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.